Transient infantile hypertriglyceridemia and hepatosteatosis Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

Regulatory Watchboard

2 events

Jan 2026ZIRGAN: New indication approved

FDAcompleted

Sep 2009

Zirgan: FDA approved

Treatment of acute herpetic keratitis (dendritic ulcers)

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Transient infantile hypertriglyceridemia and hepatosteatosis.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Zirgan

(ganciclovir)Orphan drug

Sirion Therapeutics, Inc.

Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

12.1 Mechanism of Action ZIRGAN is an antiviral drug [ see Microbiology (12.4) ] .

Approved Sep 2009FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Transient infantile hypertriglyceridemia and hepatosteatosis.
Search all trials →

Search clinical trials for Transient infantile hypertriglyceridemia and hepatosteatosis →

Recent News & Research

No recent news articles indexed yet for Transient infantile hypertriglyceridemia and hepatosteatosis.
Search PubMed for Transient infantile hypertriglyceridemia and hepatosteatosis →

Browse all Transient infantile hypertriglyceridemia and hepatosteatosis news →

Specialist Network

No specialists currently listed for Transient infantile hypertriglyceridemia and hepatosteatosis.

View all Transient infantile hypertriglyceridemia and hepatosteatosis specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰